Physician profile
Deepa Pai
NPI 1538378195
$6,117.50
in general payments reported to CMS, 2019-2025
38 companies · $989 in 2025
The $989 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $141 · 2021: $874 · 2022: $861 · 2023: $1,021 · 2024: $971 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.32 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $895.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $648.41 | 2021-2025 | |
| Lilly USA, LLC | $559.55 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $533.74 | 2019-2025 | |
| Amgen INC. | $392.51 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $379.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $259.10 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $249.86 | 2019-2025 | Gardasil 9, Lagevrio, Gardasil |
| Astellas Pharma US INC | $245.91 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $239.09 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.64 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $200.92 | 2019-2023 | |
| Amarin Pharma, INC. | $126.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $120.22 | 2021-2023 | |
| Exact Sciences Corporation | $105.02 | 2024-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.